ExpressionBenchGene expression tools

Worked example: liver cancer vs non-tumor liver

Which genes change when liver tissue becomes hepatocellular carcinoma, the most common type of liver cancer? We reanalysed a public dataset in which each patient gave both a tumor sample and a sample of nearby non-tumor liver.

Explore the full results yourself. Open this table in the DE Results tool to see the interactive volcano plot, search for any gene and run pathway enrichment.

Open in DE Results

The study

The series has 66 samples from 41 patients with hepatocellular carcinoma: 41 tumors and 25 non-tumor liver samples. Some patients were later treated with anti-PD-1 immunotherapy. The authors' own question was about fat-processing genes and response to treatment. We ask a simpler one: what differs between tumor and non-tumor liver in the same person.

Original paper: Li B and colleagues, Nanjing Drum Tower Hospital. Multiomics identifies metabolic subtypes based on fatty acid degradation allocating personalized treatment in hepatocellular carcinoma. Hepatology 2024;79(2):289-306. doi:10.1097/HEP.0000000000000553. Data: GEO GSE202069.

What we compared

We used the patients who gave both a tumor and a non-tumor sample. The 16 tumors coded “PT” come from the immunotherapy group and have no matching non-tumor sample, so they can't be part of a within-patient comparison.

We used 48 samples: 24 tumors and 24 normal, from 24 patients. The read counts are NCBI's own, made with one standard pipeline for every public human dataset. The samples used and the samples left out, with reasons are listed in full.

Quality checks

Sequencing depth. Each sample had 15.2 to 21.5 million reads counted on genes (median 18.8 million), which is plenty for this kind of analysis. See the depth of every sample.

Sample map (PCA): each dot is a sample, coloured by tumor or normal. Tumors and normal samples form two separate groups.
Sample map (PCA). Each dot is one sample; samples with similar gene activity sit close together. The horizontal direction captures 43% of all variation between samples, and it separates tumors from normal tissue.

One pair left out because its labels look swapped. For patient PS4, the sample labelled non-tumor sits among the tumors on the sample map, and the sample labelled tumor sits among the non-tumor samples. Both fail the label check. A swap of two tubes is the simplest explanation, but we can't confirm it, so we left the pair out rather than relabel it. With the pair included, 2,266 genes count as clearly changed instead of 2,612; the overall picture is the same.

The label check for every sample and a sample-to-sample similarity map are available too.

Results

Volcano plot of tumor vs normal: genes higher in tumors on the right in red, lower in tumors on the left in blue.
Volcano plot made by the DE Results tool from this table (its “Download SVG” output), so it is the same plot you get by opening the example. Each dot is a gene. Right: more active in tumors (red); left: less active (blue). Higher dots have stronger evidence. The dashed lines mark a 2-fold change and an adjusted p-value of 0.05.

Of 17,060 genes tested, 8,886 differ with an adjusted p-value below 0.05. Many of those changes are small. Requiring at least a doubling or halving leaves 672 genes up and 1,940 down in tumors.

Strongest evidence: higher in tumors

Genelog2 fold changeAdjusted p
CAP2+2.881.9e-43
CCT3+1.391.7e-33
CENPF+4.131.1e-32
IQGAP3+4.225.1e-31
PLVAP+2.359.6e-31
ASPM+3.641.6e-29
AKR1B10+5.521.9e-29
KPNA2+2.182.0e-29
MELK+4.398.7e-29
APLN+3.354.1e-28

Strongest evidence: lower in tumors

Genelog2 fold changeAdjusted p
FCN2-6.463.1e-82
CLEC4M-9.041.1e-60
CLEC4G-8.431.1e-60
PTH1R-4.592.6e-60
CFP-3.531.5e-57
FCN3-5.287.9e-57
LYVE1-3.762.5e-56
HAMP-7.281.0e-55
STAB2-4.421.4e-55
FOS-3.781.2e-52

A log2 fold change of +1 means twice as active in tumors; -3 means one eighth as active. The tables are ordered by strength of evidence, not by size of change.

Pathways

We ran the DE Results tool's own enrichment analysis on this table, with its default settings: genes at least 2-fold changed with an adjusted p-value below 0.05, gene sets of 5 to 500 genes, and the tested genes as the background. Up and down genes are tested separately. These are the same results you get by opening the example and choosing each library.

GO Biological Process: genes higher in tumors

207 of 7,038 gene sets with FDR < 0.05. Background: 12,342 tested genes in this library, 520 of them higher.

Gene setGenesFoldFDR
mitotic cell cycle process (GO:1903047)105 / 4505.52.3e-46
chromosome segregation (GO:0007059)66 / 2586.12.1e-30
nuclear chromosome segregation (GO:0098813)55 / 1757.54.3e-30
chromosome organization (GO:0051276)73 / 3365.23.2e-29
nuclear division (GO:0000280)61 / 2356.21.2e-28

Reactome: genes higher in tumors

120 of 2,038 gene sets with FDR < 0.05. Background: 8,820 tested genes in this library, 365 of them higher.

Gene setGenesFoldFDR
Cell Cycle, Mitotic100 / 4875.03.2e-41
Cell Cycle Checkpoints64 / 2546.11.6e-30
Resolution of Sister Chromatid Cohesion37 / 1147.85.4e-21
Mitotic Prometaphase45 / 1915.71.2e-19
EML4 and NUDC in mitotic spindle formation33 / 1047.72.2e-18

GO Biological Process: genes lower in tumors

612 of 7,038 gene sets with FDR < 0.05. Background: 12,342 tested genes in this library, 1,423 of them lower.

Gene setGenesFoldFDR
immune effector process (GO:0002252)100 / 2673.26.1e-25
humoral immune response (GO:0006959)67 / 1424.16.2e-23
immune response-regulating cell surface receptor signaling pathway (GO:0002768)87 / 2353.22.2e-21
activation of immune response (GO:0002253)99 / 3162.71.6e-18
complement activation (GO:0006956)32 / 436.51.6e-18

Reactome: genes lower in tumors

104 of 2,038 gene sets with FDR < 0.05. Background: 8,820 tested genes in this library, 1,063 of them lower.

Gene setGenesFoldFDR
Creation of C4 and C2 activators47 / 488.12.3e-39
Complement cascade64 / 886.03.8e-37
Initial triggering of complement50 / 567.44.3e-37
Classical antibody-mediated complement activation40 / 408.34.6e-35
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell73 / 1215.01.8e-34

“Genes” is how many of the set's genes changed, out of all the set's genes in the background. “Fold” is how many times more changed genes the set has than expected by chance. Releases: GO Biological Process ontology release 2026-07-26, human annotations generated 2026-05-21; Reactome release 98; WikiPathways release 2026-11-10. All significant gene sets from all three libraries, with their genes: enrichment.txt. The tool's library releases are refreshed monthly, so results in the tool may differ slightly from those shown here.

What the results show

These are broad patterns that match what is already known about this cancer, which is a useful sign the analysis behaves as it should. They are not new findings.

Limits

How we ran it

DESeq2 1.50.2 in R 4.5.2 (Bioconductor 3.22), comparing tumor with normal within each patient (design ~ donor + tissue). Genes were kept if they had at least 10 reads in at least 24 samples. P-values were adjusted with the Benjamini-Hochberg method, and fold changes were shrunk with apeglm 1.32.0. Each step explained in plain words.

The volcano plot and pathway results were made by the DE Results tool itself (version 0.3), run on the results table in a browser, not by separate code.

Files: full results for every tested gene · pathway results · volcano plot (SVG) · summary · downloaded files and checksums · software versions · code: download step, analysis step and tool step. The analysis ran in a fixed Bioconductor container: ghcr.io/bioconductor/bioconductor_docker@sha256:e34177896c1579f66d48b756e4229b58237499183a089da084af72d7aba1d40a.

If you use these results, please cite the original study above. Our reanalysis may differ from the authors' own results because the read counts, filtering and statistical method differ.